Quick Summary — SABS scores higher on quality with 5.0/10 vs SER's 4.9/10. SABS trades at $3.48 while SER trades at $1.76. Both analyzed daily using SEC EDGAR data across 13 institutional models.
SABS scores higher with a 5.0/10 quality rating vs SER's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $3.48, SABS trades +64.1% above its Bayesian DCF fair value of $1.25, while SER at $1.76 trades +35.5% above its estimate of $1.14. SABS shows a wider gap between price and intrinsic value.
SABS earns a Quality of Company score of 5.0/10 compared to SER's 4.9/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
SABS carries a WARN value trap risk (41/100) while SER shows LOW risk (32/100). Stocks with value trap scores above 40 may appear undervalued but face deteriorating fundamentals — declining margins, rising debt, or shrinking revenue can make the apparent discount a trap.
Both SABS and SER operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare SABS vs SER differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.